INBX Insider Trading Activity and SEC Form 4 Filings
INBX insider trading summary
Over the past 12 months, insiders at Inhibrx Biosciences, Inc. (INBX) reported 20 open-market purchases worth $6.3M by 3 insiders and 3 sales worth $164K by 1 insider on SEC Form 4. Net insider buying was $6.2M.
Latest INBX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 14, 2026 | Mark Lappe | Chief Executive Officer | Buy | $206K (2,449 @ $84.07) |
| Oct 14, 2026 | Mark Lappe | Chief Executive Officer | Buy | $210K (2,470 @ $85.00) |
| Oct 14, 2026 | Mark Lappe | Chief Executive Officer | Buy | $208K (2,451 @ $85.00) |
| Oct 14, 2026 | Mark Lappe | Chief Executive Officer | Buy | $9K (100 @ $85.76) |
| Oct 14, 2026 | Mark Lappe | Chief Executive Officer | Buy | $208K (2,470 @ $84.07) |
| Oct 14, 2026 | Mark Lappe | Chief Executive Officer | Buy | $9K (100 @ $85.76) |
| Sep 28, 2026 | Mark Lappe | Chief Executive Officer | Buy | $148K (1,500 @ $98.88) |
| Sep 28, 2026 | Mark Lappe | Chief Executive Officer | Buy | $305K (3,000 @ $101.70) |
| Sep 25, 2026 | Mark Lappe | Chief Executive Officer | Buy | $329K (3,324 @ $98.87) |
| Sep 25, 2026 | Mark Lappe | Chief Executive Officer | Buy | $217K (2,176 @ $99.60) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.